You paid $299 for a panel with 60 analytes. Ten days later a PDF arrives. Fifty-eight values sit inside the reference range. Two are printed in red.
The $299 is the part of the bill you already know about. The rest of it starts with those two red lines. That is the whole economics of large wellness panels, and almost no advertising mentions it. The sticker price buys a blood draw and a list of numbers. It does not buy the specialist visit, the repeat test, the ultrasound or the three months of worrying, and those are frequently the expensive part.
Here is a measured version of that gap. A 2019 study in JAMA Internal Medicine looked at Medicare patients having cataract surgery who received a preoperative electrocardiogram, which the researchers classify as a common low-value service in that setting. Medicare paid about $3.3 million for the electrocardiograms themselves. The downstream testing, visits and treatments that followed came to an estimated $35 million a year, with spending reaching up to $565 per beneficiary who got one. The follow-on cost ran roughly ten times the cost of the test.
This article is about money. If you want how direct-to-consumer lab services work as a category, that is a separate subject covered elsewhere in this library. Here the question is narrower: what are you buying, what would the same thing cost another way, and what happens to your wallet after the results land.
What the advertised price covers
Strip away the branding and a retail panel is three things: a blood draw, a set of measurements run by a lab, and a report.
What it does not include is the part that produces value. Nobody is paid to decide whether these tests were the right ones for you. Nobody is paid to read the results against your history, your medications and your exam. Nobody is paid to act on them.
The Food and Drug Administration makes a related point about direct-to-consumer tests in general, saying they “are not a substitute for a traditional health care evaluation.” That page is dated December 2019, so treat it as the agency’s standing framing rather than a current regulatory status report. The economic translation is blunt. You bought a measurement. Interpretation is sold separately, usually by someone who bills by the visit.
The same tests, ordered clinically, often cost less
This is the comparison the ads never make, and it is the single most useful thing in this article.
When a clinician orders a lab test because there is a medical reason for it, insurance machinery turns on. Medicare’s own consumer page says Part B covers medically necessary clinical diagnostic laboratory tests when your doctor or provider orders them, and states that “You usually pay nothing for Medicare-approved clinical diagnostic laboratory tests.” The word usually is doing honest work there, but the baseline is zero, not $299.
Commercial coverage works differently and varies by plan, but a similar structure applies. HealthCare.gov explains that most plans, including Marketplace plans, must cover a defined set of preventive services with no cost sharing, generally when an in-network provider delivers them, and that for screening tests you typically owe no copay or coinsurance even before meeting the deductible. The same page cautions that zero cost is not guaranteed in every case.
So the honest comparison is not $299 versus nothing. It is $299 versus a visit copay plus whatever your plan does with the labs, which for some tests in some plans is nothing at all.
Why a self-ordered test usually is not covered
The mechanism is simpler than people expect, and it is worth understanding because it explains a lot of surprise bills.
Coverage attaches to two things: an order from a clinician and a documented reason. A test you bought yourself has neither. There is no order in your chart and no diagnosis code explaining why the test was appropriate, so your plan has nothing to pay against. The claim does not get denied so much as it never exists.
This also means the money you spend out of pocket on a retail panel generally does not count toward your deductible. You are not making progress toward your plan’s out-of-pocket maximum. You are spending outside the system entirely.
There is a second trap worth naming. The no-cost-sharing rule applies to a defined list of preventive services, not to any test a person decides to call screening. A large wellness panel bundles plenty of analytes that appear on no required preventive list anywhere. Even ordered by a clinician, those pieces normally run through your deductible at the plan’s negotiated rate. “Covered” and “free” are different words, and a panel can be neither, one or both depending on which analyte you are looking at.
The downstream workup is the real price
Clinicians have a word for what happens next: a cascade. One borderline or incidental finding triggers a test, which triggers a referral, which triggers an imaging study, and the chain keeps going because stopping feels riskier than continuing.
A 2019 survey of practicing US internists published in JAMA Network Open put numbers on it. Among respondents, 99.4% reported having experienced cascades after incidental findings. Most reported cascades that produced no clinically important outcome. Physicians said these chains caused their patients psychological harm in 68.4% of cases and financial burden in 57.5%. Asked about their most recent cascade, 53.2% said no guidelines existed, to their knowledge, for how to follow up the finding. Roughly a third doubted that ordering the test behind the incidental finding had been clinically appropriate at all.
That last figure deserves a pause. In a third of these chains, the physician’s own view was that the triggering test probably should not have been ordered.
Imaging compounds the problem fast, because bodies are lumpy. A 2019 study in the Journal of the American Academy of Dermatology looked at 259 adults with moderate-to-severe psoriasis who had a whole-body PET/CT scan before entering clinical trials. These were people screened to be free of active infection, known cancer and uncontrolled other conditions. About 12% turned up a clinically significant incidental finding. Twenty-eight had findings that looked like they might be cancer. Six of those were cancer. That is a positive predictive value near 32%, meaning roughly two out of three people with a worrying scan result did not have the disease the scan suggested.
Now add up what those two-out-of-three people paid. A specialist consultation. A repeat scan at three months. Possibly a biopsy. None of it appeared on the original price tag.
A rough way to price the risk before you buy
You cannot predict a cascade. You can estimate its cost, and the estimate is usually clarifying.
Before buying a panel, look up what your plan charges for a specialist visit, for an ultrasound or CT, and for a day-surgery procedure such as a biopsy. If you have not met your deductible, use the full negotiated price, not the copay. Add those three numbers. That total, not the panel price, is the real range you are putting at risk.
Two federal tools help you find the numbers. Under the Centers for Medicare & Medicaid Services hospital price transparency requirements, which took effect January 1, 2021, every US hospital must post a machine-readable file of all items and services plus a consumer-friendly display of shoppable services. April 1, 2026 is the date CMS has set to start enforcing the updated requirements in its CY 2026 outpatient rule. Separately, CMS’s No Surprises guidance describes a good faith estimate for uninsured and self-pay patients, with a dispute process the agency illustrates using 2022 services: a final bill at least $400 above the estimate could be disputed within 120 days of the bill date.
Why more analytes is usually worse value
The marketing logic is that 90 tests must be better than 20. The arithmetic says the opposite.
A reference range is built from results in a large group of healthy people, and by the usual convention it covers the middle 95% of them. That means roughly 1 in 20 perfectly healthy people falls outside the range on any given test. Run enough tests on a healthy person and at least one flag becomes close to inevitable: with 20 independent measurements, the chance of a completely clean sheet is about 36%, so roughly two-thirds of healthy people collect at least one red line. The construction of reference ranges gets a full treatment elsewhere in this library, so take the short version here.
Note what that means for pricing. Each extra analyte adds a few dollars to the panel and a meaningful chance of adding a cascade. The cheap part scales linearly. The expensive part scales with the number of chances to be flagged.
This is why “comprehensive” is a strange word to pay extra for in this category. In most consumer purchases, more features means more value, and the instinct carries over. With testing on a person who feels fine, the relationship inverts past a certain point. Each additional measurement has a low chance of catching something that matters and a steady chance of producing a number that is merely unusual. A panel marketed as the most complete option on the menu is, in plain terms, the option most likely to hand you a problem you did not have when you woke up.
The counterargument is real and deserves saying: sometimes a broad panel does catch something early, and for that one person it was worth every dollar. The trouble is that the people buying these panels are mostly people who feel fine, and in that group the flagged-but-harmless results vastly outnumber the real catches.
MedlinePlus, the National Library of Medicine’s consumer service, makes the underlying point without the arithmetic: an out-of-range result does not automatically mean a health problem, healthy people often fall outside the range, and eating, medications, exercise and whether you followed the prep instructions all move results. Labs also use different methods and different ranges, so results are not comparable across labs.
When a panel is genuinely worth paying for
This is not a case against ever buying a test with your own money. There are situations where it is the rational move.
You have a specific question, not a general curiosity. “Is my ferritin still low after six months of treatment” is a question. “Let’s see what’s going on in there” is not.
Someone will act on the result. Before you buy, know who reads it and what they would do with each possible answer. If the answer to every result is “interesting,” skip it.
You have a known risk that justifies monitoring. A documented deficiency, a family history your clinician has flagged, a medication that requires periodic labs.
The cash price genuinely beats your coverage. On a high-deductible plan, before the deductible is met, a retail price can be lower than the negotiated rate you would owe. Check both numbers instead of assuming.
Access is the actual barrier. If the alternative is waiting eleven weeks for an appointment and you will bring the results to that appointment anyway, paying out of pocket can buy time rather than waste money.
The honest counterweight: none of those scenarios describes a 60-analyte panel bought on a whim. They describe one or two specific tests bought for a stated reason.
What to settle before you order a panel
Take them one at a time. Any one of them can end the purchase.
- What decision will this change? Write down the two or three possible results and what you would do after each. If the actions are identical, the information is not worth money.
- Who will interpret it? Name the person. “I’ll figure it out online” is not an answer, and a lab report without clinical context is where cascades begin.
- What would this cost ordered normally? Call your plan or check the hospital’s posted shoppable services file. Some of these tests are covered at no cost sharing when a clinician orders them.
- What is my exposure if one value comes back flagged? Use the specialist visit plus imaging plus procedure estimate from above.
- Do I have symptoms? If yes, a panel is the wrong purchase. You need an appointment, where the testing will be targeted and probably covered.
- Does the panel include anything no professional body recommends for screening? The US Preventive Services Task Force grades screening recommendations for people with no signs or symptoms of the condition being evaluated, and it does not consider cost in those grades. A test nobody recommends for asymptomatic people is being sold on comprehensiveness, not evidence.
- Will I get the raw data? If the product only returns a wellness score rather than the actual values and the lab’s own reference ranges, a clinician cannot use it and you have bought a number you cannot act on.
When to skip the panel and get seen
Some situations call for a clinician now, not a shopping decision.
If you have chest pain or pressure, trouble breathing, unexplained weight loss, blood in your stool or urine, a new lump, persistent fever, or a symptom that has been getting worse for weeks, do not order a panel and wait ten days for a PDF. Make an appointment. Symptoms change what gets tested, and they change how the testing is paid for.
If a panel you already bought returns a value the lab has marked as critical, such as a severely abnormal potassium, glucose or hemoglobin, call a clinician that day rather than waiting for a routine visit. Bring the full report with the lab’s own reference ranges, since those ranges differ between labs.
And if a clinician proposes further testing after a flagged result, it is reasonable to ask what the test would change and what happens if you wait and repeat the original measurement instead. The ABIM Foundation’s Choosing Wisely campaign, an eleven-year effort that began in 2012 and has since concluded, generated more than 700 recommendations from over 80 specialty societies about tests and treatments that are commonly overused. Those lists remain a useful reference even though the campaign has ended.
The number to run before you buy
Take the advertised price of the panel. Then take your plan’s cost for one specialist visit, one imaging study and one minor procedure, at full pre-deductible price. Add those three.
That second number, not the first, is what you are really deciding about. It is usually several times the panel price, and in the cataract study above the follow-on spending ran about ten times what the test itself cost. The odds of triggering some part of it rise with every extra analyte on the menu.
A panel bought to answer one question you have already written down is usually a reasonable purchase. A panel bought because 60 numbers sounds thorough is a bet that none of those 60 numbers comes back red, and that is a bet the arithmetic says you lose.
Keep exploring: organic price premium and supplement cost per serving.
Sources
- Centers for Medicare & Medicaid Services (Medicare.gov). “Clinical laboratory tests.”
- HealthCare.gov, Centers for Medicare & Medicaid Services. “Preventive care benefits.” healthcare.gov
- Centers for Medicare & Medicaid Services. “Hospital Price Transparency.” cms.gov
- Centers for Medicare & Medicaid Services. “No Surprises: Understand your rights against surprise medical bills.” cms.gov
- U.S. Food and Drug Administration. “Direct-to-Consumer Tests.” fda.gov
- MedlinePlus, U.S. National Library of Medicine. “How to Understand Your Lab Results.” medlineplus.gov
- U.S. Preventive Services Task Force. “About the USPSTF.” uspreventiveservicestaskforce.org
- ABIM Foundation. “Choosing Wisely: Patient Resources.”
- PubMed. “Ganguli I, Lupo C, Mainor AJ, et al. "Prevalence and Cost of Care Cascades After Low-Value Preoperative Electrocardiogram for Cataract Surgery in Fee-for-Service Medicare Beneficiaries." JAMA Internal Medicine, 2019. DOI: 10.1001/jamainternmed.2019.1739.” doi.org
- PubMed. “Ganguli I, Simpkin AL, Lupo C, et al. "Cascades of Care After Incidental Findings in a US National Survey of Physicians." JAMA Network Open, 2019. DOI: 10.1001/jamanetworkopen.2019.13325.” doi.org
- PubMed. “Wan MT, Torigian DA, Alavi A, et al. "Prevalence of clinically significant incidental findings by whole-body fludeoxyglucose F 18 positron emission tomography/computed tomography scanning in moderate-to-severe psoriasis patients participating in clinical trials." Journal of the American Academy of Dermatology, 2019. DOI: 10.1016/j.jaad.2019.01.008.” doi.org